Lilly’s Mirikizumab shows reduction of Intestinal Inflammation in Crohn’s Disease
Eli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreEli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreAbbott declared the first patient has been enrolled in the DISTINCT study (Dorsal spInal cord STImulatioN vs mediCal management for
Read moreSwiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read morePhase 3 clinical trials for the COVID-19 vaccine named AZD1222, developed by AstraZeneca and Oxford University, have been paused after
Read moreEli Lilly and Company announced the start of BLAZE-2, a Phase 3 study of the monoclonal antibody LY-CoV555 vaccine candidate
Read moreSanofi and GSK are in preliminary talks with the European Commission (EC) on the supply of up to 300 million
Read moreResults from the ongoing Phase I/II COVID-19 vaccine trial, led by the University of Oxford, showed the AZD1222 vaccine developed
Read moreModerna’s COVID-19 vaccine candidate generated antibodies in all 45 patients studied in its early stage human trial, the U.S biotech
Read moreAt a time when pharma and biotech companies worldwide are racing to develop a vaccine, researchers at the University of
Read moreThe World Health Organization (WHO) and the Democratic Republic of Congo (DRC) government announced on June 25 that the second-largest
Read more